Qyuns Therapeutics-B (02509) Enters into an Exclusive Licensing Agreement with CALDERA THERAPEUTICS for a Preclinical Bispecific Antibody Project Targeting TL1A and IL-17

Zhitong Finance APP news, Qyuns Therapeutics-B (02509) announced that on November 5, 2026, the company entered into an out-licensing agreement with Caldera Therapeutics, Inc. for a preclinical-stage bispecific antibody project targeting TL1A and IL-17 (specifically IL-17A and IL-17A/F).